The Body Covers: The 35th Annual Meeting of the Infectious Diseases Society of America
An Open Label Pilot Study for the Efficacy and Tolerability of Once Daily DDI Versus Twice Daily DDI
Dr. P. Keiser and colleagues from the Southwestern Medical center in Dallas reported on their findings in an open label trial comparing ddI given once or twice a day. The patients were nucleoside analog experienced and had median viral loads greater than 100,000 copies/ml. Changes in viral load were comparable between the two groups at about one half log at 8 weeks. One person in the bid group developed pancreatitis, and 3 qd patients complained of gi intolerance and stopped medication. 5/8 patients in each arm were judged to be adherent to the study regimen. In summary, the once daily dosing of ddI seemed comparable to the twice daily regimen in terms of antiviral activity and tolerability in this preliminary study.
This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.